1. Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strains.
- Author
-
Matthias KA, Reveille A, Connolly KL, Jerse AE, Gao YS, and Bash MC
- Subjects
- Animals, Antibodies, Bacterial, Antigens, Bacterial genetics, Bacterial Outer Membrane Proteins genetics, Cross Reactions, Immunogenicity, Vaccine, Mice, Neisseria meningitidis immunology, Rabbits, Serogroup, Bacterial Outer Membrane Proteins immunology, Meningococcal Infections prevention & control, Meningococcal Vaccines immunology, Neisseria meningitidis, Serogroup B genetics, Neisseria meningitidis, Serogroup B immunology, Porins genetics
- Abstract
Detergent-extracted detoxified outer membrane vesicle (dOMV) vaccines are effective at preventing invasive serogroup B meningococcal (MenB) disease caused by the homologous Neisseria meningitidis strain from which they are produced, but offer limited protection from heterologous strains. Differences in vaccine efficacy are partially due to strain-specific variations in the antigenic sequence types and expression levels of outer membrane proteins (OMPs), including the immunodominant OMP PorA. In this study, dOMV vaccines deficient in major OMPs, including PorA, PorB, and RmpM were isolated and used to immunize rabbits and mice. Serum samples were obtained from each animal and tested for antibody responses against five MenB strains. Immunization with wild type dOMVs elicited antibodies to major antigens including PorA, PorB, RmpM, and lipooligosaccharide (LOS), and demonstrated limited bactericidal activity against heterologous strains. In contrast, OMP-deficient dOMV vaccines elicited broadly cross-reactive bactericidal antibodies, with PorA/PorB-dual deficient dOMVs inducing antibodies exhibiting the greatest cross-reactivity. Enhanced killing of heterologous strains correlated with binding to unique protein bands in immunoblots, suggestive of improved immunogenicity of antigens under-represented in the wild type vaccine., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [K. A. M. and M. C. B. are named as inventors on patent applications in the area of meningococcal and gonococcal vaccines. Rights to these inventions have been assigned to the U.S. Food and Drug Administration. All other authors report no potential conflicts of interest. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the U.S. Food and Drug Administration, the Uniformed Services University of the Health Sciences, or the Department of Defense]., (Published by Elsevier Ltd.)
- Published
- 2020
- Full Text
- View/download PDF